PPD

Worldwide Corporate Headquarters
929 North Front Street
Wilmington
North Carolina
28401
United States

Tel: 910-251-0081
Fax: 910-762-5820

Email: ppdinfo@ppdi.com

Show jobs for this employer

About PPD

PPD is a leading global contract research organization providing comprehensive, integrated drug development, laboratory and lifecycle management services. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 47 countries and approximately 20,000 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a firm commitment to quality to help clients and partners bend the cost and time curve of drug development and optimize value in delivering life-changing therapies to improve health.

413 articles with PPD

  • PPD, Inc. (Nasdaq: PPD ), was named the Clinical Research Company of the Year for winning multiple awards at the PharmaTimes Clinical Researcher of the Year competitions. In addition to PPD winning the highest honor at the PharmaTimes International Clinical Researcher of the Year 2020 virtual awards ceremony, individual PPD clinical researchers won gold and bronze in both the Clinical Research Associate (CRA) and

  • PPD, Inc. (Nasdaq:PPD), a leading global contract research organization, will host a conference call on Wednesday, Oct. 28, 2020, at 9 a.m. (U.S. Eastern Time) to discuss its third quarter 2020 financial results. Investors and other interested parties may listen to a live webcast of the conference call by logging onto the investors section of PPD’s website at https://investors.ppd.com . An archive copy of the webcast w

  • PPD, Inc. (Nasdaq: PPD ), a leading global contract research organization, has achieved the internationally recognized information security certification ISO/IEC 27001:2013, demonstrating the company’s commitment to ensuring the protection of its customers’ data. ISO/IEC 27001:2013 is an information security standard published by the International Organization for Standardization (ISO), the world’s largest develop

  • PPD, Inc., a leading global contract research organization, announced the pricing of an underwritten public offering by certain stockholders of the Company, including stockholders affiliated with Hellman & Friedman LLC and The Carlyle Group Inc., of 38,000,000 shares of the Company’s common stock at a price to the public of $32.25 per share.

  • PPD, Inc. (Nasdaq: PPD ), has been recognized as a top employer in Bulgaria, adding to the global contract research organization’s growing list of accolades as an employer of choice around the world. PPD was recognized as a top 50 desirable employer in Bulgaria, according to the second annual Employer of Choice Survey organized by the employer brand and business consulting agency To The Top. The organization sel

  • PPD, Inc. announced that certain stockholders of the Company, including stockholders affiliated with Hellman & Friedman LLC and The Carlyle Group Inc., have commenced an underwritten public offering of 38,000,000 shares of the Company’s common stock pursuant to a registration statement filed with the Securities and Exchange Commission.

  • PPD, Inc., a leading global contract research organization, updated its financial guidance for the third quarter ending September 30, 2020.

  • PPD, Inc. (Nasdaq: PPD ) has earned recognition for its global employee learning and development program in the Brandon Hall Group Human Capital Management (HCM) Excellence in Learning Awards . PPD was recognized with the Brandon Hall Gold Award in two categories – “best use of blended learning” for its clinical foundation progra

  • PPD, Inc. (Nasdaq: PPD ), a leading global contract research organization, and Lupus Therapeutics (LT), an affiliate of the Lupus Research Alliance known for its lupus clinical trials expertise, have entered into a collaboration to expand and enhance lupus clinical research for PPD’s pharmaceutical and biotech customers. This press release features multimedia. View the full release here: https://www.businesswire.c

  • PPD, Inc., a leading global contract research organization, has been named to Forbes magazine’s 2020 list of America’s Best-in-State Employers for North Carolina.

  • PPD, Inc., a leading global contract research organization, reported its financial results for the second quarter ended June 30, 2020.

  • PPD, Inc. (Nasdaq: PPD ), a leading global contract research organization, today announced it has signed a new three-year agreement with Pfizer Inc. to provide drug development services to advance Pfizer’s portfolio. Under the terms of the agreement, Pfizer has the right to extend the term for additional two-year periods. Financial details of the agreement were not disclosed. The agreement builds on the companies’ e

  • PPD, Inc. (Nasdaq:PPD), a leading global contract research organization, will host a conference call on Wednesday, Aug. 5, 2020, at 8:30 a.m. (U.S. Eastern Time) to discuss its second quarter 2020 financial results.

  • PPD, Inc. (Nasdaq: PPD ) has expanded its laboratory test portfolio by adding five new molecular, serology and functional assays designed expressly for COVID-19 vaccine and therapy development programs. These assays have been developed by PPD ® Laboratories’ bioanalytical, biomarker and vaccines sciences labs to run on multiple assay platforms and are compatible with high-throughput liquid handling so they can support

  • PPD, Inc., a leading global contract research organization, announced that Jaguar Holding Company II and PPD Development, L.P., both indirect wholly owned subsidiaries of the Company, successfully upsized and finalized the terms of the Co-Issuers’ offering of $500 million aggregate principal amount of 4.625% senior notes due 2025 and $700 million aggregate principal amount 5.000% senior notes due 2028.

  • PPD, Inc., a leading global contract research organization, announced that it intends to offer $700 million in aggregate principal amount of senior notes, subject to market and other conditions.

  • PPD, Inc. has been recognized for excellence in clinical research for the ninth consecutive year by pharmaceutical and biotech professionals surveyed for Life Science Leader magazine’s 2020 CRO Leadership Awards.

  • PPD, Inc., a leading global contract research organization, reported its financial results for the first quarter ended March 31, 2020.

  • PPD, Inc. (Nasdaq: PPD ), a leading global contract research organization, has extended its digital clinical trial solutions to support biopharma companies’ research continuity initiatives and to help ensure patient safety as part of its integrated response to the COVID-19 pandemic. PPD’s extensive, flexible suite of digital trial solutions – from electronic patient consent to telehealth to hybrid and fully dece

  • PPD, Inc. (Nasdaq:PPD), a leading global contract research organization, today announced it will release its first quarter 2020 results after market close on Wednesday, May 6, 2020.